MA-ALAKA’I-TECHNOLOGIES
29.5.2019 23:02:12 CEST | Business Wire | Press release
Today, Alaka’i Technologies unveiled Skai, the world’s first hydrogen fuel cell powered air mobility solution designed to transform the way the world moves. From its sleek, uncluttered design, radically simple and safe electric vertical takeoff and landing (eVTOL) vehicle, to its fuel source - a system that runs entirely on hydrogen fuel cells - Skai is poised to be one of the safest, cleanest and most versatile air mobility solutions introduced to the world.
Skai’s core team members are nationally-recognized aerospace experts, engineers, and veteran pilots who have served in top-level positions at NASA, Raytheon, Beech, Cirrus, DayJet, and the Department of Defense who collaborated on the vision of solving some of the world’s most-pressing global challenges across transportation, energy and the environment. Skai is co-designed by Designworks, the design innovation studio for the BMW Group, to leverage its creative expertise to help shape a world-class vehicle. The result is Skai, stripped away of all unnecessary complexity, waste and possible points of failure, leaving the most essential elements for the craft and optimizing them for the most intuitive experience.
“This remarkably impressive team have come together to build on our collective experience to finally realize our singular, critical vision to launch Skai and transform transportation,” said Brian Morrison, Co-Founder, President and Chief Technology Officer of Alaka’i Technologies. “Skai offers practical, real-life solutions to everything from relieving traffic congestion to delivering supplies during natural disasters. Skai is set to offer affordable, realistic applications in the commercial, private, freight, and personal air mobility markets.”
The heart of Skai, and one of its most revolutionary features, is the use of hydrogen fuel cells, a clean environmental solution from end to end. With the advantage of being 95% reusable and the remaining (99%) recyclable, Skai’s hydrogen fuel cells offer reliable, safe and environmentally clean emission comprised solely of heat and water. This is a stark alternative to traditional fuel and battery sources. Hydrogen fuel cells allow Skai to travel further distances and carry a greater payload.
“Air mobility is a very exciting and fascinating topic,” said Holger Hampf, President of Designworks. “Our focus for this project was to help build a new consumer facing brand from scratch - considering and designing all touchpoints - digital, physical and service. And as a result, delivering an all-encompassing user-centric experience which is purposeful and highly desirable in all aspects.”
Alaka’i Technologies has initiated their test program with the FAA. Pending certification, Skai will create new possibilities in personal mobility for everyone, efficient emergency responses, economical freight distribution, and the utilization of hydrogen fuel cells as a highly reliable, zero-emission power source.
Skai Highlights Include:
- Co-designed by Designworks with inherent quality craftsmanship
- Powered by clean hydrogen fuel cells, with zero emissions
- Range: Up to 4 Hours, ~400 Miles
- Six reliable, quiet, efficient electric motors with designed-in redundancy
- Seats up to five passengers
- Reliable, fault-tolerant architecture for safety and security
- Piloted version launched first, with autonomous versions to follow
- Designed for the ultimate in safety, with an Airframe Parachute
For more information: http://skai.co .
ABOUT ALAKA’I
Alaka’i Technologies is an emerging air mobility design and manufacturing company, headquartered in Hopkinton MA. Founded by Brian Morrison in 2015, Alaka’i Technologies assembled a distinguished executive team with decades of aerospace development, production, executive and airspace integration experience (NASA, Raytheon, Beech Aircraft, McDonnell Douglas, Hughes, DayJet, SATSAir, Cirrus, Metro Aviation, Delta Airlines) and FAA certification experience. Working together since the 1990’s on industry-defining projects such as the NASA AGATE and SATS Programs, they also built and flew the world’s first-ever Fly-By-Light aircraft. Today, the Alaka'i team is engineering proprietary, progressive air mobility solutions to offer point A-to-Anywhere transportation that are clean, simple, safe, and accessible for everyone. Ultimately, transforming transportation through hydrogen-powered mobility.
ABOUT DESIGNWORKS
Designworks is the design innovation studio for the BMW Group. Designworks is ‘the architect of future’ — designing holistic systems that impact and improve the world we live in. Designworks inspires and challenges the companies it works with to be and stay at the forefront of their industries in design, technology and innovation. For 25 years it has been stimulating the BMW Group as well as a select group of companies with ambitious visions for the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005834/en/
Contact:
John Moore Press@alakai.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom